Gene therapy's debated cancer risk moves from theory to documented cases
STAT News reports that a small number of tumour cases now provide strong evidence that AAV vectors used in gene therapy can, in rare instances, cause cancer — a risk long debated in the field.
For years, researchers in gene therapy have debated whether adeno-associated viral (AAV) vectors — the delivery vehicles most commonly used to ferry replacement genes into cells — could, in rare circumstances, trigger tumour formation through insertional mutagenesis or related mechanisms. According to reporting by STAT News, a small number of cases now provide what the article describes as strong evidence that this risk is real.
The report arrives in the same news cycle as continued coverage of the Novartis Zolgensma safety signal: seven cases of tumour development have been acknowledged in children treated with Zolgensma, the AAV9-based gene therapy for spinal muscular atrophy (SMA). That story was covered in Genetic Current on 6 November and again on 8 November 2026 in the context of the American Heart Association meeting; the new STAT item broadens the frame beyond any single product to the class-level question of AAV oncogenicity.
The STAT article is behind a paywall and full methodology details are not accessible from the lede alone. The reporting indicates that researchers are not interpreting the cases as a reason to abandon AAV-based gene therapy, but that the field will need to grapple seriously with long-term post-treatment surveillance, vector integration-site analysis, and risk–benefit communication with patients and families. Regulatory agencies, including the FDA, have previously required long-term follow-up studies for approved gene therapies; this emerging evidence is likely to inform how those requirements are applied and enforced going forward.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Gene therapy uses specially engineered viruses called AAV vectors to carry a working copy of a faulty gene into a patient's cells. Scientists have long wondered whether these viruses could, very rarely, cause cancer by disrupting other genes when they insert into DNA. A report by STAT News says a small number of cases now give strong evidence that this can happen in rare instances.
This news relates to ongoing discussion about Zolgensma, a gene therapy used in young children with a serious muscle-wasting condition called spinal muscular atrophy. Researchers say the cases do not mean gene therapy should stop, but that doctors and scientists need to monitor patients carefully over many years and think carefully about how to explain the risks and benefits to families.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-09STAT+: Gene therapy's long-debated cancer risk materializes